LABORIE completes acquisition of BUCK Elektromedizin and BUCKmeditec

Laborie Medical Technologies, Inc. ("LABORIE"), based in Toronto, Ontario, has completed its acquisition of BUCK Elektromedizin GmbH and BUCKmeditec GmbH & Co. Bad Rappenaeau, Germany based BUCK develops and distributes innovative and advanced biofeedback and electrical stimulation equipment, accessories and consumables for pelvic floor dysfunction in the treatment of urinary and fecal incontinence.

"Both LABORIE and BUCK have a shared commitment to helping healthcare professionals deliver better products and services, and to make life more rewarding and dignified for those who use our products," stated Brian Ellacott, LABORIE President and CEO. "By combining existing product lines with BUCK's extensive customer base, we can provide a greater breadth of innovative products and services to enable German urologists to deliver better care to their patients."

LABORIE's acquisition of BUCK further extends its market leadership in Pelvic Muscle Rehabilitation. The acquisition also expands LABORIE's presence in the German market by adding 15 in-country sales representatives that will market the full range of both LABORIE and BUCK products.

BUCK managing director Franz Dettling said, "We are excited to partner with a global leader in urology who will help us expand the breadth of our offering to German urologists as well as help provide access to our unique pelvic therapy offerings around the world."

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Non-invasive imaging technique can accurately detect clear-cell renal cell carcinoma